
About Nxera Pharma
Nxera Pharma is a publicly listed company based in Tokyo (Japan) founded in 1990. GPCR-targeted therapeutics are developed for various diseases. It operates on a HealthTech model. The company has 374 employees. Its website nxera.life draws about 16 thousand monthly visits. Nxera Pharma offers products and services including HTL0039732. Its focus areas include Pharmaceuticals and Biotechnology.
Company details
Nxera Pharma is engaged in the development of innovative medicines aimed at transforming lives. The company is involved in the healthcare sector, specifically in pharmaceuticals and biotechnology. Emphasis is placed on accelerating drug development through investment in science and technology. Solutions are pursued to achieve breakthroughs in treatment, particularly in areas like cancer immunotherapy. Structure-based drug design is revolutionized by embracing advanced technology. Partnerships are sought to drive once-in-a-generation discoveries for patients in need.
- Headquarters Tokyo, Japan
- Employees 374
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website nxera.life
- Social LinkedIn X YouTube
- Legal Name Nxera Pharma Co., Ltd.
- Annual Revenue$188.99 M (USD)2.71as on Dec 31, 2025
- Net Profit-$79.98 M (USD)-158.99as on Dec 31, 2025
- EBITDA-$23.68 M (USD)-168.84as on Dec 31, 2025
- Latest Funding Round$53.11M (USD), Post-IPO
Nov 2023
- InvestorsEuropean Union
& 1 more
- Employee Count374
Products & Services of Nxera Pharma
Nxera Pharma offers a comprehensive portfolio of products and services, including HTL0039732.
Investigational treatment developed for cancer immunotherapy in trials.
Apps and channels of Nxera Pharma
its YouTube channel Nxera has 150 subscribers.
Funding Insights of Nxera Pharma
- Total Rounds 2
- Last Round Post-IPO β $53.11M
- First Round $363,317
(Sep 2021)
- Investors Count 2
All 2 funding rounds of Nxera Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2023 | $53.11M | Post-IPO | β | β | |
| Sep 2021 | $363,317 | Grant | β | β |
2 investors in total: 2 institutional.
Investors in Nxera Pharma
Nxera Pharma has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include European Union and OPF1 fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Investor details for Nxera Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Nxera Pharma
65 people are tracked at Nxera Pharma (33 in leadership, 32 in team); the tracked headcount is 374.
| Name | Role | Group |
|---|---|---|
Sophie Bradley | Director (translational Biology) | Leadership |
Jayesh Patel | Director, Protein Engineering | Leadership |
Mathieu Rappas | Senior Director Protein Sciences | Leadership |
Nigel Swain | Vice President, Head Of Discovery | Leadership |
Giselle Wiggin | Senior Director | Leadership |
Chris Cargill | President and Chief Executive Officer | Leadership |
Greg Sissons | Director, Head Of Procurement | Leadership |
Paul S. | Vice President Enterprise Portfolio Management | Leadership |
Toshihiro Maeda | Chief Operating Officer And President Of Nxera Pharma Japan | Leadership |
Marianne Muldbjerg | Head Of Site Operations | Leadership |
Lara Kitchin | Legal Director | Leadership |
Marcus Messenger | Head Of Business Development | Leadership |
Claire Teague | Director, Head Of Translational Biomarkers & Bioinformatics | Leadership |
Candelle Chong | Executive Vice President, Chief Of Staff | Leadership |
Gerard Collins | Human Resources Director | Leadership |
Catherine Tighe | Associate Director | Leadership |
Mariko Nakafuji | Chief Legal Officer | Leadership |
Michelle Fairey Assoc Cipd | Senior HR Business Partner | Leadership |
Helen Carberry | Head Of Human Resources | Leadership |
Steve Watson | Senior Director Of Chemistry At Nxera Pharma | Leadership |
45 more people are available in the full profile.
Complete people profiles for Nxera Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Nxera Pharma
Nxera Pharma is a publicly listed company on the TSE with ticker symbol 4565 in Japan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date08 Feb 2019
- Listed onFRA: JSS
- Listed entityNxera Pharma Co., Ltd.
- Exchange sectorHealth technology
- ISINJP3431300007
- Share price1,183.00 JPY (-3.03% on the day) · 2026-10-14
- Market capitalisation112,989,012,909.00 JPY
- EPS (diluted, trailing year)-88.88 JPY
- Volume (last session)835,900
Financials of Nxera Pharma
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 29.61B JPY | -12.53B JPY | -3.71B JPY |
| 2024 | 28.84B JPY | -4.84B JPY | -1.38B JPY |
| 2023 | 12.77B JPY | -7.19B JPY | -6.58B JPY |
| 2022 | 15.57B JPY | 382.0M JPY | 4.16B JPY |
| 2021 | 17.71B JPY | 1.02B JPY | 8.19B JPY |
Detailed financial statements for Nxera Pharma
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Nxera Pharma
4 dated milestones of Nxera Pharma across 33 years, from founding to its latest funding, stage changes and deals.
- Founded Nxera Pharma is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $363K.
- Funding Latest funding round, Post-IPO, of $53.1M.
Web traffic of Nxera Pharma
The website of Nxera Pharma (nxera.life) receives about 16.3K visits a month and ranks #1,116,988 among all websites worldwide, #1,383 in Biotechnology and Pharmaceuticals.
- Monthly visits16.3K
▼ 15.4% vs previous month
- Unique visitors8.2K
per month
- Global rank#1,116,988
among all websites
- Category rank#1,383
Health · Biotechnology and Pharmaceuticals
- Bounce rate39%
- Pages per visit3.3
- Average visit56 sec
- DevicesDesktop 43% Β· Mobile 57%
Websites whose visitors overlap most with Nxera Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
answers.ten-navi.com | answers.ten-navi.com | 100% | #1,204,032 | β | |
| boehringer-ingelheim.com | 60% | 1.6M | #39,825 | View details | |
| fiercepharma.com | 40% | #124,066 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Nxera Pharma
Complete news archive for Nxera Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nxera Pharma
Nxera Pharma was founded in 1990 and raised its 1st funding round 31 years after it was founded.
Nxera Pharma is headquartered in Tokyo, Japan. It is registered at Tokyo, Tokyo, Japan.
Nxera Pharma has 374 employees.
Annual revenue of Nxera Pharma is $188.99M as on Dec 31, 2025.
Nxera Pharma is engaged in the development of innovative medicines aimed at transforming lives. The company is involved in the healthcare sector, specifically in pharmaceuticals and biotechnology. Emphasis is placed on accelerating drug development through investment in science and technology. Solutions are pursued to achieve breakthroughs in treatment, particularly in areas like cancer immunotherapy. Structure-based drug design is revolutionized by embracing advanced technology. Partnerships are sought to drive once-in-a-generation discoveries for patients in need.
Nxera Pharma offers HTL0039732.
Yes, Nxera Pharma is publicly traded on TSE under the ticker symbol 4565.
Nxera Pharma has 2 investors. Key investors include European Union, and OPF1 fund.
